CAS 571190-30-2

Palbociclib

Descripción:

Palbociclib es un medicamento oral clasificado como un inhibidor selectivo de las quinasas dependientes de ciclinas 4 y 6 (CDK4/6), utilizado principalmente en el tratamiento del cáncer de mama positivo para receptores hormonales y negativo para el receptor 2 del factor de crecimiento epidérmico humano. Su fórmula química es C24H29N5O2, y presenta una estructura compleja que incluye un anillo de piridazina, que es crucial para su actividad biológica. Palbociclib actúa interrumpiendo el ciclo celular, inhibiendo específicamente la transición de la fase G1 a la fase S, evitando así la proliferación de células cancerosas. La sustancia se administra típicamente en combinación con inhibidores de la aromatasa o antagonistas del receptor de estrógenos para mejorar la eficacia terapéutica. Palbociclib se caracteriza por su solubilidad moderada en disolventes orgánicos y su relativamente baja solubilidad en agua, lo que puede influir en su biodisponibilidad. Su farmacocinética indica un metabolismo de primer paso significativo, principalmente por el hígado, y tiene una vida media que apoya la dosificación una vez al día. Al igual que con muchas terapias dirigidas, es esencial monitorear los efectos secundarios como la neutropenia durante el tratamiento.

Fórmula: C₂₄H₂₉N₇O₂

InChI: InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)

Clave InChI: InChIKey=AHJRHEGDXFFMBM-UHFFFAOYSA-N

SMILES: O=C1N(C=2C(C(C)=C1C(C)=O)=CN=C(NC3=CC=C(C=N3)N4CCNCC4)N2)C5CCCC5

Sinónimos:

• 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)pyrido[2,3-d]pyridin-7(8H)-one
• 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one
• 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one
• 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one
• Ibrance
• Otava-Bb 1115529
• Palbociclib
• Palbociclib base
• Palbocyclib
• Pd 332991
• Pd 991
• Pd-0332991
• Pd0332991

Palbociclib

CAS: 571190-30-2

Palbociclib

Pureza: ≥98%

Peso molecular: 447.53g/mol

Ref: 54-BUP14421

Palbociclib

CAS: 571190-30-2

Fórmula: C₂₄H₂₉N₇O₂

Forma y color: Yellow Solid

Peso molecular: 447.54

Ref: 4Z-P-196001

Palbociclib

CAS: 571190-30-2

Forma y color: Neat

Ref: 86-MM3729.00

Palbociclib

CAS: 571190-30-2

Fórmula: C₂₄H₂₉N₇O₂

Pureza: >97.0%(T)(HPLC)

Forma y color: White to Yellow to Yellow green powder to crystal

Peso molecular: 447.54

Ref: 3B-P3315

Palbociclib

CAS: 571190-30-2

Palbociclib is an oral CDK4/6 inhibitor, halts Rb phosphorylation, arrests cell cycle, and curbs tumor growth.

Fórmula: C₂₄H₂₉N₇O₂

Pureza: 98% - 99.9%

Forma y color: Solid

Peso molecular: 447.53

Ref: TM-T1785

Palbociclib

CAS: 571190-30-2

Fórmula: C₂₄H₂₉N₇O₂

Pureza: (TLC) ≥ 98.0%

Forma y color: Yellow powder

Peso molecular: 447.53

Ref: 7W-GX0330

Palbociclib

CAS: 571190-30-2

Applications Palbociclib (also known as compound number PD-0332991) is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
References Finn, R., et al.: Breast Cancer Res., 11, 5 (2009);

Fórmula: C₂₄H₂₉N₇O₂

Forma y color: Neat

Peso molecular: 447.53

Ref: TR-P139900

Palbociclib Sulfate Sodium Salt

Producto controlado

CAS: 571190-30-2

Applications Palbociclib Sulfate is a derivative of Palbociclib (P139900) which is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
References Finn, R., et al.: Breast Cancer Res., 11, 5 (2009)

Fórmula: C₂₄H₂₈N₇NaO₅S

Forma y color: Neat

Peso molecular: 549.58

Ref: TR-P139905

Palbociclib-d4

Producto controlado

CAS: 571190-30-2

Applications Palbociclib-d4 is an isotope labelled compound of Palbociclib (P139900). Palbociclib (P139900) is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
References Finn, R., et al.: Breast Cancer Res., 11, 5 (2009)

Fórmula: C₂₄H₂₅D₄N₇O₂

Forma y color: Light Yellow

Peso molecular: 451.56

Ref: TR-P139901

Palbociclib - Bio-X ™

CAS: 571190-30-2

This product is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

Fórmula: C₂₄H₂₉N₇O₂

Pureza: Min. 95%

Forma y color: Powder

Peso molecular: 447.53 g/mol

Ref: 3D-BP166224

Palbociclib

CAS: 571190-30-2

Selective and potent inhibitor of cyclin-dependent kinases CDK4 and CDK6. It blocks cell cycle progression from phase G1 into S by inhibiting CDK4/6-dependent retinoblastoma (RB) phosphorylation. It has been used for the treatment of HER2 negative, estrogen receptor (ER) positive metastatic breast cancer.

Fórmula: C₂₄H₂₉N₇O₂

Pureza: Min. 95%

Forma y color: Powder

Peso molecular: 447.53 g/mol

Ref: 3D-FA65120

Palbociclib-d4 Hydrochloride

Producto controlado

CAS: 571190-30-2

Applications Palbociclib-d4 Hydrochloride is an intermediate in synthesizing Palbociclib-d4 (P139901), an isotope labelled compound of Palbociclib (P139900). Palbociclib (P139900) is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
References Finn, R., et al.: Breast Cancer Res., 11, 5 (2009)

Fórmula: C₂₅H₂₇D₄N₇O₂·HCl

Forma y color: Neat

Peso molecular: 502.04

Ref: TR-P139937

Palbociclib N-Beta-D-Glucuronide Sodium Salt (Technical Grade, ~65%)

Producto controlado

CAS: 571190-30-2

Applications Palbociclib N-β-D-Glucuronide is a derivative of Palbociclib (P139900) which is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
References Finn, R., et al.: Breast Cancer Res., 11, 5 (2009)

Fórmula: C₃₀H₃₆N₇NaO₈

Pureza: ~65%

Forma y color: Neat

Peso molecular: 645.64

Ref: TR-P139910

Palbociclib

CAS: 571190-30-2

Pureza: 95%

Forma y color: Solid

Peso molecular: 447.5429993

Ref: 10-F794410

Maillard Product

Producto controlado

CAS: 571190-30-2

Fórmula: C₃₆H₄₉N₇O₁₂

Forma y color: Neat

Peso molecular: 771.814

Ref: TR-M411860

6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)pyrido[2,3-d]pyridin-7(8H)-one

CAS: 571190-30-2

Fórmula: C₂₄H₂₉N₇O₂

Forma y color: Solid

Peso molecular: 447.5328

Ref: IN-DA00367H